| Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay WM Szejniuk, M Cekala, M Bøgsted, C Meristoudis, T McCulloch, ... Cancer treatment and research communications 27, 100318, 2021 | 7 | 2021 |
| BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study A Louw, V Panou, WM Szejniuk, C Meristoudis, SM Chai, C van Vliet, ... Journal of Thoracic Oncology 17 (7), 921-930, 2022 | 27 | 2022 |
| BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy V Panou, A Louw, WM Szejniuk, C Meristoudis, SM Chai, LL Andersen, ... European Respiratory Journal 56 (suppl 64), 2020 | 1 | 2020 |
| Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics S Pedersen, KP Jensen, B Honoré, SR Kristensen, CH Pedersen, ... Clinical proteomics 19 (1), 2, 2022 | 23 | 2022 |
| Clinical and Translational Radiation Oncology WM Szejniuk, MS Nielsen, D Brønnum, Z Takács-Szabó, UM Weinreich, ... Imaging 2008, 58-0028, 2019 | | 2019 |
| Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma LA Lynggård, V Panou, W Szejniuk, OD Røe, C Meristoudis Journal of the American Society of Cytopathology 11 (6), 385-393, 2022 | 8 | 2022 |
| Does timing of palliative chemotherapy influence survival in advanced lung adenocarcinoma? K Nowicka-Matus, WM Szejniuk, T McCulloch, UGI Falkmer | | 2017 |
| Dynamic risk prediction of 30-day mortality in patients with advanced lung cancer: comparing five machine learning approaches C Vesteghem, WM Szejniuk, RF Brøndum, UG Falkmer, CA Azencott, ... JCO Clinical Cancer Informatics 6, e2200054, 2022 | 2 | 2022 |
| Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation WM Szejniuk, T McCulloch, OD Røe Case Reports 2014, bcr2014204809, 2014 | 4 | 2014 |
| Elevated mean fractional exhaled nitric oxide and radiation pneumonitis in patients with non-small cell lung cancer WM Szejniuk, MS Nielsen, DS Brønnum, Z Takács‐Szabó, UM Weinreich, ... | | 2018 |
| Encefalopatia niedotlenieniowo-niedokrwienna u noworodków W Szejniuk, M Szymankiewicz Perinatologia, Neonatologia i Ginekologia 1, 85-93, 2008 | 7 | 2008 |
| Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art WM Szejniuk, AI Robles, T McCulloch, UGI Falkmer, OD Røe The Pharmacogenomics Journal 19 (1), 5-14, 2019 | 44 | 2019 |
| Fractional exhaled nitric oxide as a potential biomarker for radiation pneumonitis in patients with non-small cell lung cancer: a pilot study WM Szejniuk, MS Nielsen, D Brønnum, Z Takács-Szabó, UM Weinreich, ... Clinical and translational radiation oncology 19, 103-109, 2019 | 15 | 2019 |
| High-dose thoracic radiation therapy for non-small cell lung cancer: a novel grading scale of radiation-induced lung injury for symptomatic radiation pneumonitis WM Szejniuk, MS Nielsen, Z Takács-Szabó, J Pawlowski, SS Al-Saadi, ... Radiation Oncology 16, 1-11, 2021 | 5 | 2021 |
| Identifying metabolic alterations in newly diagnosed small cell lung cancer patients P Shona, JB Hansen, RG Maltesen, WM Szejniuk, T Andreassen, ... Elsevier, 2021 | | 2021 |
| Identifying metabolic alterations in newly diagnosed small cell lung cancer patients S Pedersen, JB Hansen, RG Maltesen, WM Szejniuk, T Andreassen, ... Metabolism Open 12, 100127, 2021 | 12 | 2021 |
| Inter-expert observer variance of organs at risk according to the DAHANCA guidelines K Jensen, E Lorentzen, JG Eriksen, J Johansen, N Gyldenkerne, ... Radiotherapy and Oncology 182 (Suppl. 1), S582-S584, 2023 | 1 | 2023 |
| Interobserver variation in organs at risk contouring in head and neck cancer according to the DAHANCA guidelines CP Nielsen, EL Lorenzen, K Jensen, JG Eriksen, J Johansen, ... Radiotherapy and Oncology 197, 110337, 2024 | 1 | 2024 |
| LBA99 First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line … A Helland, VD Haakensen, AK Ojlert, SMH Thunold, AK Nowak, WL Chin, ... Annals of Oncology 34, S1337, 2023 | 1 | 2023 |
| Makrosomia i inne zaburzenia występujące u noworodka matki z cukrzycą W Szejniuk, M Szymankiewicz Perinatologia, Neonatologia i Ginekologia 1 (4), 253-259, 2008 | 17 | 2008 |
